Vita Coco Insider: CFO Reports Two Stock Sales and Lists Option Holdings
Rhea-AI Filing Summary
Corey Baker, Chief Financial Officer of Vita Coco Company, Inc. (COCO), reported two sales of common stock under a Rule 10b5-1 plan. The filings show a sale of 1,000 shares on 09/05/2025 at $38.00 and a sale of 1,000 shares on 09/08/2025 at $38.51, reducing his beneficially owned common stock to 41,754 shares. The report also lists outstanding non-qualified stock options exercisable into common stock: 14,205 shares at a $16.91 strike, 13,481 at $24.35, 8,746 at $26.18, 11,547 at $27.59 and 13,218 at $33.36, each held directly. Several option grants have scheduled vesting dates and installment vesting schedules as described by the reporting person.
Positive
- Transactions executed under a Rule 10b5-1 plan, indicating pre-established trading instructions and compliance with insider trading protocols
- Detailed option and vesting schedules disclosed, providing transparency about future potential dilution and executive alignment with equity
Negative
- Reduction in direct common stock holdings from 42,754 to 41,754 shares following the reported sales
Insights
TL;DR: Routine insider sales under a 10b5-1 plan; no new equity issuance or debt changes reported.
The Form 4 discloses two small open-market sales by the CFO executed pursuant to a pre-established Rule 10b5-1 trading plan, which suggests these transactions follow a predetermined schedule rather than opportunistic timing. The filing confirms continued equity exposure via substantial outstanding options across multiple strike prices and staggered vesting schedules. There is no indication in the filing of additional corporate actions or material changes to capital structure.
TL;DR: Disclosure is compliant and shows typical officer liquidity within a structured trading plan.
The report includes required details: transaction dates, amounts, prices, ownership after sale, and explanatory vesting terms for options. Use of a Rule 10b5-1 plan is explicitly noted, which supports an affirmative defense to insider trading claims so long as plan conditions were met. The attestation by an attorney-in-fact is present. No governance irregularities or departures are disclosed.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 1,000 | $38.51 | $39K |
| Sale | Common Stock | 1,000 | $38.00 | $38K |
| holding | Non-Qualified Stock Option (right to buy) | -- | -- | -- |
| holding | Non-Qualified Stock Option (right to buy) | -- | -- | -- |
| holding | Non-Qualified Stock Option (right to buy) | -- | -- | -- |
| holding | Non-Qualified Stock Option (right to buy) | -- | -- | -- |
| holding | Non-Qualified Stock Option (right to buy) | -- | -- | -- |
Footnotes (1)
- The sales of shares of common stock reported were effected pursuant to a Rule 10b5-1 trading plan. The stock option vests in four equal annual installments beginning on March 10, 2024. The stock option is vested as to 40% and will vest the remaining 30% on March 10, 2025, 20% on March 10, 2026 and 10% on March 10, 2027. The stock option vests in four equal annual installments beginning on March 4, 2025. The Reporting Person was granted stock options that will vest in four annual equal installments on each anniversary of the grant date provided that the Reporting Person remains in continuous service on each vesting date.
